Please use this identifier to cite or link to this item:
Title: Predicted basal metabolic rate and cancer risk in the European Prospective Investigation into Cancer and Nutrition
Author: Kliemann, Nathalie
Murphy, Neil
Viallon, Vivian
Freisling, Heinz
Tsilidis, Konstantinos K.
Rinaldi, Sabina
Mancini, Francesca Romana
Fagherazzi, Guy
Boutron-Ruault, Marie-Christine
Boeing, Heiner
Schulze, Matthias B.
Masala, Giovanna
Krogh, Vittorio
Sacerdote, Carlotta
Santucci de Magistris, Maria
Bueno de Mesquita, H. Bas
Weiderpass, Elisabete
Kühn, Tilman
Kaaks, Rudolf
Jakszyn, Paulka
Redondo Sánchez, Daniel
Amiano, Pilar
Chirlaque, María Dolores
Barricarte, Aurelio
Ericson, Ulrica
Drake, Isabel
Nøst, Therese Haugdahl
Aune, Dagfinn
May, Anne M.
Tjønneland, Anne
Dahm, Christina Catherine
Overvad, Kim
Tumino, Rosario
Quirós, J. Ramón
Trichopoulou, Antonia
Karakatsani, Anna
Vecchia, Carlo La
Nilsson, Lena Maria
Riboli, Elio
Huybrechts, Inge
Gunter, Marc J.
Keywords: Càncer
Issue Date: 1-Aug-2020
Publisher: Wiley
Abstract: Emerging evidence suggests that a metabolic profile associated with obesity may be a more relevant risk factor for some cancers than adiposity per se. Basal metabolic rate (BMR) is an indicator of overall body metabolism and may be a proxy for the impact of a specific metabolic profile on cancer risk. Therefore, we investigated the association of predicted BMR with incidence of 13 obesity-related cancers in the European Prospective Investigation into Cancer and Nutrition (EPIC). BMR at baseline was calculated using the WHO/FAO/UNU equations and the relationships between BMR and cancer risk were investigated using multivariable Cox proportional hazards regression models. A total of 141,295 men and 317,613 women, with a mean follow-up of 14 years were included in the analysis. Overall, higher BMR was associated with a greater risk for most cancers that have been linked with obesity. However, among normal weight participants, higher BMR was associated with elevated risks of esophageal adenocarcinoma (hazard ratio per 1-standard deviation change in BMR [HR1-SD]: 2.46; 95% CI 1.20; 5.03) and distal colon cancer (HR1-SD: 1.33; 95% CI 1.001; 1.77) among men and with proximal colon (HR1-SD: 1.16; 95% CI 1.01; 1.35), pancreatic (HR1-SD: 1.37; 95% CI 1.13; 1.66), thyroid (HR1-SD: 1.65; 95% CI 1.33; 2.05), postmenopausal breast (HR1-SD: 1.17; 95% CI 1.11; 1.22) and endometrial (HR1-SD: 1.20; 95% CI 1.03; 1.40) cancers in women. These results indicate that higher BMR may be an indicator of a metabolic phenotype associated with risk of certain cancer types, and may be a useful predictor of cancer risk independent of body fatness.
Note: Versió postprint del document publicat a:
It is part of: International Journal of Cancer, 2020, vol. 147, num. 3, p. 648-661
Related resource:
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
KliemannN.pdf988.37 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.